HIO Healthcare Inv

TIDMCOS

Collagen Solutions PLC

21 August 2018

Collagen Solutions Plc

(the "Company" or the "Group")

Appointment of Distributors in China

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces it has signed distribution agreements with two new Chinese channel partners, Dakewe Biotech Co., Ltd and Shanghai Regenic Biomedical.

The appointment of these channel partners follows the restructuring of the Company's presence in China and the securing of export licences earlier this year. This is in line with the Company's stated strategy to gain more flexibility in engaging with and providing technical support to customers in China, enabling it to take advantage of opportunities within this significant territory.

Dakewe Biotech Co., Ltd was founded in 1999, with headquarters in Shenzhen, subsidiary offices in Beijing, Shanghai, Hong Kong, Guangzhou, Wuhan and Chengdu. Dakewe has over 400 employees serving an existing and growing customer base of over 10,000 also working with over 2,000 sub agents throughout China. Their primary business includes developing and manufacturing of diagnostic reagents and medical devices and the distribution of life science reagents, foreign and domestic scientific instruments and medical equipment throughout China. They will distribute Collagen Solutions' products to the research market and engage in business to business sales to the medical device industry.

Shanghai Regenic Biomedical is a company recently established by an experienced biomedical executive in China with the purpose of selling and distributing collagen-based products to the medical device and regenerative medicine sectors.

Both distributors bring different market access, qualities and advantages, both will be key in the development of Collagen Solutions' sales and distribution channels within China.

Jamal Rushdy, CEO of Collagen Solutions, said: "We have made good progress since our restructuring in China and the addition of these two new channel partners is testament to the growth opportunity for us there. We have been working hard to secure these distribution agreements and with these in place, we are now well positioned to engage further with customers in China. We look forward to working closely with our new distributors and growing our presence in the region."

Enquiries:

 
 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                                     Via Walbrook 
 Hilary Spence, CFO 
 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Steve Cox (Corporate Finance)                                   Tel: 0207 397 8900 
 Stephen Keys 
 
 Walbrook PR Ltd                      Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Anna Dunphy                                                     Mob: 07876 741 001 
 Helen Cresswell                                                 Mob: 07841 917 679 
 
 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRASEISUSFASEIA

(END) Dow Jones Newswires

August 21, 2018 02:00 ET (06:00 GMT)

Healthcare Inv (LSE:HIO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

Healthcare Inv (LSE:HIO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025